Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Filter bei nächster Suche beibehalten
language:"Undetermined"
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?filter%5B%5D=language%3A%22Undetermined%22&lookfor=%22Recruitment+Status%3A+Authorised-recruitment+may+be+ongoing+or+finished%22&type=Subject&page=3
/vufind/Search/Results?filter%5B%5D=language%3A%22Undetermined%22&lookfor=%22Recruitment+Status%3A+Authorised-recruitment+may+be+ongoing+or+finished%22&type=Subject&page=3
Search /vufind/Search2/Results?filter%5B%5D=language%3A%22Undetermined%22&lookfor=%22Recruitment+Status%3A+Authorised-recruitment+may+be+ongoing+or+finished%22&type=Subject&page=3
PubPharm (1.244)
21
Vemurafenib (vem), cobimetinib (cobi) & atezolizumab (atezo) triplet combination in advanced melanoma : A PHASE III, DOUBLE-BLINDED, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB PLUS COBIMETINIB AND VEMURAFENIB VERSUS PLACEBO PLUS COBIMETINIB AND VEMURAFENIB IN PREVIOUSLY UNTREATED BRAFV600 MUTATION-POSITIVE PATIENTS WITH METASTATIC OR UNRESECTABLE LOCALLY ADVANCED MELANOMA
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
22
Nonrelapsing secondary progressive multiple sclerosis (NRSPMS) study of Bruton tyrosine kinase (BTK) inhibitor tolebrutinib SAR442168 (HERCULES) : A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with nonrelapsing secondary progressive multiple sclerosis - HERCULES
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
23
Nonrelapsing secondary progressive multiple sclerosis (NRSPMS) study of Bruton tyrosine kinase (BTK) inhibitor tolebrutinib SAR442168 (HERCULES) : A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with nonrelapsing secondary progressive multiple sclerosis - HERCULES
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
24
Relapsing Forms of multiple sclerosis (RMS) study of Bruton's Tyrosine Kinase (BTK) inhibitor Tolebrutinib (SAR442168) (GEMINI 1) : A Phase 3, randomized, double-blind efficacy and safety study comparing SAR442168 to teriflunomide (Aubagio®) in participants with relapsing forms of multiple sclerosis - GEMINI 1
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
25
Myelofibrosis: Phase 3 Study of Navitoclax Plus Ruxolitinib Versus Ruxolitinib : A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Navitoclax in Combination with Ruxolitinib Versus Ruxolitinib in Subjects with Myelofibrosis - TRANSFORM-1
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
26
Relapsing Forms of multiple sclerosis (RMS) study of Bruton's TyrosineKinase (BTK) inhibitor Tolebrutinib (SAR442168) (GEMINI 1) : A Phase 3, randomized, double-blind efficacy and safety study comparing SAR442168 to teriflunomide (Aubagio®) in participants with relapsing forms of multiple sclerosis - GEMINI 1
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
27
Chemoradiotherapy +/- pembrolizumab in participants with MIBC : A Phase 3, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) versus CRT Alone in Participants with Muscle-invasive Bladder Cancer (MIBC) (KEYNOTE-992)
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
28
COVID-19 vaccine immunology : COVID-19 vaccine immunological studies in Finland
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
29
The Cold Fluids Study : Rapid infusion of Ringer's lactate solution at different temperatures and the effects on circulation and perfusion in healthy volunteers – a randomized crossover trial
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
30
Master Protocol for Avelumab Continuation Study : AVELUMAB MASTER PROTOCOL: AN OPEN-LABEL CONTINUATION STUDY FOR PARTICIPANTS CONTINUING FROM PFIZER SPONSORED AVELUMAB CLINICAL STUDIES
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
[1]
« Vorheriger
1
2
3
4
5
6
7
8
9
10
11
Nächster »
[125]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Clinical Studies
Patente
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Ihre gewählten Filter
Filter bei nächster Suche beibehalten
Filter aufheben
Sprache: Unbestimmt
Medienart
1.244
Aufsätze
1.244
E-Artikel
1.244
E-Ressourcen
Zeitschriftentitel
1.244
WHO International Clinical Trials Registry Plat...
Thema
1.244
610
1.244
Recruitment Status: Authorised-recruitment may ...
1.244
Study Type: Interventional
334
Phase: Phase 3
156
Phase: Phase 2
120
Phase: Phase 4
36
Medical Condition: Relapsing Multiple Sclerosis...
34
Phase: Phase 1
28
Medical Condition: Primary Progressive Multiple...
26
Medical Condition: Non-relapsing Secondary Prog...
24
Medical Condition: Muscle Invasive Bladder Canc...
22
Medical Condition: Myelofibrosis MedDRA version...
16
Medical Condition: MULTIPLE MYELOMA MedDRA vers...
14
Medical Condition: Unresectable locally advance...
10
Medical Condition: HIV Infection;Therapeutic ar...
10
Medical Condition: Rheumatoid Arthritis MedDRA ...
8
Medical Condition: ;Therapeutic area: Diseases ...
8
Medical Condition: Solid Tumors MedDRA version:...
6
Medical Condition: ;Therapeutic area: Analytica...
6
Medical Condition: Asthma;Therapeutic area: Dis...
Alle anzeigen ...
weniger ...
Erscheinungszeitraum
434
2020-
810
2010-2019
Erscheinungsjahr(e)
Von:
Bis:
Sprache
Unbestimmt
Haven't found what you're looking for?
Wird geladen...